Published in Clin Exp Metastasis on December 20, 2009
Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol (2010) 1.23
Tissue factor, blood coagulation, and beyond: an overview. Int J Inflam (2011) 1.05
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. Cancer Res (2011) 0.98
Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging. PLoS One (2013) 0.88
Kallikrein 6 is a novel molecular trigger of reactive astrogliosis. Biol Chem (2012) 0.87
Protease-activated receptors (PARs)-biology and role in cancer invasion and metastasis. Cancer Metastasis Rev (2015) 0.80
Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins. Cancer Metastasis Rev (2010) 0.78
Retracted MDA-9/syntenin is essential for factor VIIa-induced signaling, migration, and metastasis in melanoma cells. J Biol Chem (2014) 0.76
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell (1991) 11.51
Thrombin signalling and protease-activated receptors. Nature (2000) 9.27
Melanoma. N Engl J Med (2006) 8.80
Proteinase-activated receptors. Pharmacol Rev (2001) 5.02
Protease-activated receptors: contribution to physiology and disease. Physiol Rev (2004) 4.49
PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell (2005) 3.92
Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One (2007) 2.77
Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol (1990) 2.69
Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med (1998) 2.42
Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev (2005) 2.42
Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res (2004) 1.68
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer (2003) 1.62
Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. J Biol Chem (2001) 1.52
Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood (1998) 1.42
The role of altered cell-cell communication in melanoma progression. J Mol Histol (2004) 1.34
The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene (2001) 1.29
Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res (2001) 1.28
Human melanoma: development and progression. Cancer Metastasis Rev (1990) 1.24
Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem (2003) 1.19
Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol (2005) 1.10
Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev (2007) 1.08
The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ (1997) 1.07
The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res (1995) 1.06
Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics (2008) 1.03
Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol (2006) 1.02
Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. Cancer Res (2009) 1.02
Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res (2001) 0.99
Correlation of protease-activated receptor-1 with differentiation markers in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis. Clin Cancer Res (2004) 0.93
Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF. Histopathology (2008) 0.91
Effect of interleukin-1-beta on metastasis formation in different tumor systems. J Natl Cancer Inst (1991) 0.89
Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin Cancer Res (1996) 0.88
Double transfection improves small interfering RNA-induced thrombin receptor (PAR-1) gene silencing in DU 145 prostate cancer cells. FEBS Lett (2004) 0.87
'Proteolytic switching': opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer (1999) 0.85
Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorg Med Chem Lett (1999) 0.84
Expression of functional protease-activated receptor 1 in human prostate cancer cell lines. Urol Res (2003) 0.84
The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol Oncol (2006) 0.82
A ribonuclease protection assay-based approach for analysis of angiogenic gene expression in archival tissues. Diagn Mol Pathol (2007) 0.75
Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71
Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol (2002) 2.27
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res (2003) 2.14
Adiponectin and hypertension in normal-weight and obese children. Am J Hypertens (2012) 2.09
Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia (2006) 1.98
Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy (2005) 1.67
Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol Life Sci (2011) 1.62
Molecular epidemiology of norovirus infections in sporadic cases of viral gastroenteritis among children in Northern Italy. J Med Virol (2006) 1.47
Increased DC trafficking to lymph nodes and contact hypersensitivity in junctional adhesion molecule-A-deficient mice. J Clin Invest (2004) 1.47
Clinical and mutational spectrum of Mowat-Wilson syndrome. Eur J Med Genet (2005) 1.46
A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood (2002) 1.45
The adaptor protein p66Shc is a positive regulator in the angiogenic response induced by hypoxic T cells. J Leukoc Biol (2009) 1.40
p66SHC promotes apoptosis and antagonizes mitogenic signaling in T cells. Mol Cell Biol (2004) 1.38
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods (2005) 1.32
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res (2011) 1.28
Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol (2005) 1.25
Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J (2004) 1.21
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res (2004) 1.19
The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med (2011) 1.16
Unique regulation of CCL18 production by maturing dendritic cells. J Immunol (2003) 1.14
Idiopathic central diabetes insipidus is associated with abnormal blood supply to the posterior pituitary gland caused by vascular impairment of the inferior hypophyseal artery system. J Clin Endocrinol Metab (2004) 1.10
Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol (2005) 1.10
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res (2002) 1.09
A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. Hum Gene Ther (2002) 1.08
An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene (2004) 1.07
Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood (2003) 1.07
Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J Med Chem (2006) 1.05
Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther (2004) 1.05
Changes in interleukin-6 and IGF system and their relationships in placenta and cord blood in newborns with fetal growth restriction compared with controls. Eur J Endocrinol (2006) 1.04
Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics (2008) 1.03
Menstrual pattern and menstrual disorders among adolescents: an update of the Italian data. Ital J Pediatr (2012) 1.02
Generation and characterization of a mouse lymphatic endothelial cell line. Cell Tissue Res (2006) 1.02
Endocrine aspects of coeliac disease. J Pediatr Endocrinol Metab (2003) 1.01
Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol (2003) 1.00
Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma. J Pathol (2006) 1.00
Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res (2008) 0.99
Update on age at menarche in Italy: toward the leveling off of the secular trend. J Adolesc Health (2009) 0.99
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther (2005) 0.98
Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Horm Res (2003) 0.98
Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol (2013) 0.98
Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism. Basic Clin Pharmacol Toxicol (2007) 0.97
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res (2003) 0.96
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol (2007) 0.95
Placental determinants of fetal growth: identification of key factors in the insulin-like growth factor and cytokine systems using artificial neural networks. BMC Pediatr (2008) 0.95
Early response to bleomycin is characterized by different cytokine and cytokine receptor profiles in lungs. Am J Physiol Lung Cell Mol Physiol (2004) 0.95
Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res (2003) 0.95
Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle (2012) 0.94
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem (2010) 0.94
Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem (2008) 0.93
Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol (2006) 0.93
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res (2006) 0.93
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther (2012) 0.92
Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer (2006) 0.92
Effects of cord serum insulin, IGF-II, IGFBP-2, IL-6 and cortisol concentrations on human birth weight and length: pilot study. PLoS One (2011) 0.92
Hypoxia influences the cellular cross-talk of human dermal fibroblasts. A proteomic approach. Biochim Biophys Acta (2007) 0.92
European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency. Horm Res (2002) 0.92
Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells. Cancer Res (2009) 0.92
Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. J Med Chem (2004) 0.92
A complex of α6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. EMBO Mol Med (2012) 0.91
Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles. J Med Chem (2009) 0.90
Regulation of HMG-CoA reductase expression by hypoxia. J Cell Biochem (2008) 0.90
Thrombin enhancement of interleukin-1 expression in mononuclear cells: involvement of proteinase-activated receptor-1. Cytokine (2002) 0.90
Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res (2012) 0.90
Inflammation is a modulator of the insulin-like growth factor (IGF)/IGF-binding protein system inducing reduced bioactivity of IGFs in cystic fibrosis. Eur J Endocrinol (2006) 0.90
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia (2009) 0.89
Epidemiological aspects of human rotavirus infection in children hospitalized with acute gastroenteritis in an area of northern Italy. Acta Biomed (2004) 0.89
Thrombin-mediated IL-10 up-regulation involves protease-activated receptor (PAR)-1 expression in human mononuclear leukocytes. J Leukoc Biol (2005) 0.89
Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm (2007) 0.89
Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging. PLoS One (2013) 0.88
Markers of insulin sensitivity in placentas and cord serum of intrauterine growth-restricted newborns. Clin Endocrinol (Oxf) (2009) 0.88
A proteomic approach for the identification of vascular markers of liver metastasis. Cancer Res (2009) 0.87
Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. Eur J Cancer (2008) 0.87
Circulating proinflammatory peptides related to abdominal adiposity and cardiometabolic risk factors in healthy prepubertal children. Eur J Endocrinol (2011) 0.86
Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines. Eur J Med Chem (2008) 0.86
Growth hormone impaired secretion and antipituitary antibodies in patients with coeliac disease and poor catch-up growth after a long gluten-free diet period: a causal association? Eur J Pediatr (2006) 0.86
p66Shc is involved in promoting HIF-1alpha accumulation and cell death in hypoxic T cells. J Cell Physiol (2007) 0.86
Hypoxia affects dendritic cell survival: role of the hypoxia-inducible factor-1α and lipopolysaccharide. J Cell Physiol (2012) 0.85
Analysis of bone mineral density and turnover in patients with cystic fibrosis: associations between the IGF system and inflammatory cytokines. Horm Res (2006) 0.85
Changes and relationships of IGFS and IGFBPS and cytokines in coeliac disease at diagnosis and on gluten-free diet. Clin Endocrinol (Oxf) (2007) 0.85
2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors. Eur J Med Chem (2010) 0.85
A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol (2010) 0.85
Potential antagonism of tubulin-binding anticancer agents in combination therapies. Clin Cancer Res (2005) 0.85
Blood pressure monitoring in children undergoing food challenge: association with anaphylaxis. Ann Allergy Asthma Immunol (2012) 0.85